Imedica SA specialises in the development and commercialisation of healthcare technologies, including the design and implementation of medical devices and systems. Their Research and Development infrastructure relates to environmental physiology, clinical testing and drug development. They also conduct extensive testing for medical devices, clothing and pharmaceuticals. During the past decade, they have become one of the most dynamic private enterprises in Romania.
Imedica SA was founded in 1991, with the mission to integrate into one company all processes a pharmaceutical product undergoes until reaching the patient, ultimately providing to the end customer a high level of healthcare.
Imedica SA is registering, importing, promoting, selling and finally delivering, in over 600 cities and villages throughout Romania, from Bucharest to the most remote place of the country. They are proud to be one of the very few companies integrated into offering a complete and diverse service, to more than 3000 satisfied customers, from pharmacies, other warehouses and hospitals.
Imedica SA is engaging into contributing through its specialists to the discovery of new molecules and is verifying the viability of new combinations in pharmaceutical industry. Its Researsch & Development department is focusing in the development of in-house projects, as well as projects conducted in cooperation with traditional partners.
What differentiated them from the competition in the past was being the only company having a distribution network, in a market when pharmacists had to drive long hours to get to Bucaresti for a box of drugs, in order to take it back to their pharmacy and sell it.
Today 25 years later, and keeping the customer oriented approach, IMEDICA has grown from working with one small pharmaceutical company and having sales of just a few thousands of boxes per year, to exclusively representing all Greek pharmaceutical major players, local Romanian producers and Cipla India, reaching sales of some millions.
“This project has received funding from the European Union’s Horizon 2020 research and innovation
programme under the Marie Skłodowska-Curie grant agreement No 691061”